Check Before You Invest : Norris Medicines Ltd

Snapshot

Q.1 Which industry/sub-sector does Norris Medicines Ltd belong to?

Norris Medicines Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Norris Medicines Ltd a good quality company?

Norris Medicines Ltd is a quality company, based on a 10-year financial track record.

Q.3 Is Norris Medicines Ltd undervalued or overvalued?

Norris Medicines Ltd appears Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Norris Medicines Ltd a good buy now?

Norris Medicines Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Norris Medicines Ltd?

Norris Medicines Ltd revenue growth is 3.2% for FY-2025, which is above its 5-year CAGR of -5.78%, indicating faster growth.

Q.2 Return on capital employed (ROCE) of Norris Medicines Ltd?

Norris Medicines Ltd Return on capital employed is -10.11% for FY-2025, which is below its 5-year historical median of -8.64%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Norris Medicines Ltd?

Norris Medicines Ltd Return on Asset is -9.47%, which is above its 5-year historical median of -13.88%, indicating improved asset utilization efficiency.

Q.4 Cash conversion cycle of Norris Medicines Ltd?

Norris Medicines Ltd Cash conversion cycle is 217 days, above its 5-year historical median of 107 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

Q.5 Gross Profit margin of Norris Medicines Ltd?

Norris Medicines Ltd Gross profit margin which is the profit after deduction of direct costs, is -11% for FY-2025, which is in line with its 5-year median of -11%, indicating stable margins.

Q.6 Operating Profit Margin of Norris Medicines Ltd?

Norris Medicines Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -4.52% for FY-2025, which is below its 5-year median of -2.89% indicating decreasing margins.

Q.7 Net Profit Margin of Norris Medicines Ltd?

Norris Medicines Ltd Net Profit Margin is -21.26% for FY-2025, is in line with with its 5-year median of -21.26%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-11	-11
Operating Profit Margin	-4.52	-2.89
Net Profit Margin	-21.26	-21.26

Q.8 Debt to Equity ratio of Norris Medicines Ltd?

Norris Medicines Ltd Debt-to-Equity ratio is -1.45, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.9 Debt to cash flow from operations of Norris Medicines Ltd?

Norris Medicines Ltd Debt to cash flow from operations is 42.31, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Norris Medicines Ltd?

Promoters hold 34.01% of the Norris Medicines Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Norris Medicines Ltd vs industry peers?

Norris Medicines Ltd revenue CAGR is -5.78%, compared to the industry median CAGR of 8.30%, indicating stable growth and maintaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	3.2	8.3
Gross Profit Growth	0	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.45	0.81
ROE	-	9.49
ROCE	-10.11	11.91
Cash Conversion Cycle (days)	216.6	85

Valuation & price assessment

Q.1 Stock return of Norris Medicines Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 4.47% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-	4.5%	7.2%	-12.9%

Q.3 Valuation ratios of Norris Medicines Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	-21.99	31.09
Price to Book	-0.94	-1.10	2.85
Price to Sales	1.51	2.10	2.79
EV to EBITDA	71.6	-74.86	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Force Motors Ltd.

2. KEI Industries Ltd.

3. Aadhar Housing Finance Ltd.

4. State Bank Of India

5. Power Finance Corporation Ltd.